Ltr Pharma Limited

LTP.ASX

Health Care

The Company is a drug development, research and repurposing company, focused on men's health and, currently, commercialising a 'first-in-class' rapid onset, on demand therapeutic nasal spray for the treatment of erectile dysfunction.

Market Data

Price

$0.375

+0.0%
Market Cap

$67.3M

P/E Ratio

-100000.0x

EPS

$-0.049

Div. Yield

0.00%

52-Week Change

-0.3%

Latest Earnings

Appendix 4D and Half Yearly Report

26 February 2026

Revenue
$0.59
+30.0% YoY
NPAT
-$5.76
-140.0% YoY
EPS
$-0.03

LTR Pharma posted a 30% increase in revenue to $587k but losses deepened significantly to $5.8M (up 140%) as the biotech company accelerated spending on R&D and commercial preparation. Key milestones included surpassing 1,000 SPONTAN prescriptions under TGA Special Access, Phase II study approvals, and strategic positioning for US ROXUS launch in H1 2026. Key points: Revenue grew 30% to $587k with strong momentum in SPONTAN prescriptions; Surpassed 1,000 SPONTAN prescriptions under TGA Special Access Scheme; Received Phase II HREC approval and TGA clinical trial clearance for SPONTAN study

Recent Announcements

26 Feb 2026 Actual Results Negative

Appendix 4D and Half Yearly Report

LTR Pharma posted a 30% increase in revenue to $587k but losses deepened significantly to $5.8M (up 140%) as the biotech company accelerated spending on R&D and commercial preparation. Key milestones included surpassing 1,000 SPONTAN prescriptions under TGA Special Access, Phase II study approvals, and strategic positioning for US ROXUS launch in H1 2026. Key points: Revenue grew 30% to $587k with strong momentum in SPONTAN prescriptions; Surpassed 1,000 SPONTAN prescriptions under TGA Special Access Scheme; Received Phase II HREC approval and TGA clinical trial clearance for SPONTAN study

Get real-time alerts for LTP

Receive AI-powered earnings summaries and instant notifications when Ltr Pharma Limited releases results.

Register Free